← Guides

What does a Qualified Person check before certifying a batch under EU GMP Annex 16?

By Savi C., Co-Founder · Published Nov 16, 2026

What certification means

Annex 16 describes batch release as three steps: checking the manufacture and testing of the batch against defined release procedures, certification of the finished batch by a QP, and transfer to saleable stock or export. Certification is the quality release. It can only be performed by a QP of a manufacturer or importer described in the marketing authorisation.

The marketing authorisation holder keeps ultimate responsibility for the product over its lifetime. The QP’s responsibility is narrower and sharper: that each individual batch was manufactured and checked in compliance with the laws of the Member State where certification takes place, the marketing authorisation and GMP. The current Annex 16 came into operation on April 15, 2016.

What the QP checks before certifying

Paraphrased from Annex 16 sections 1.6 and 1.7. The first group the QP must personally ensure. The rest may be delegated.

Personal responsibilities (1.6)

  • Certification is permitted under the terms of the manufacturing and importation authorisation
  • Any additional duties of national legislation are met
  • The certification is recorded in a register or equivalent document

Supply chain, sites and materials (1.7.2 to 1.7.10)

  • The full supply chain of the active substance and product is documented and available, preferably as a diagram
  • Audits of manufacturing, testing and active substance sites are done and the reports are available to the QP
  • All sites, manufacturing and testing activities are consistent with the marketing authorisation
  • Starting and packaging materials come from compliant sources and meet their specifications
  • Active substances were made under GMP, and excipients under the GMP required by the Directive

The batch itself (1.7.1, 1.7.11 to 1.7.13)

  • All manufacture and testing followed GMP
  • All records are complete and endorsed by appropriate personnel, and all required in-process controls and checks were made
  • Processes remain in the validated state and personnel are trained and qualified
  • Finished product test data complies with the specification in the marketing authorisation, or the authorised real time release testing programme

Changes, investigations and the wider system (1.7.14 to 1.7.21)

  • Post-marketing commitments are addressed and ongoing stability data still supports certification
  • The impact of any change has been evaluated and any additional checks are complete
  • All investigations for the batch, including out of specification and out of trend investigations, are complete enough to support certification
  • Open complaints, investigations or recalls do not negate certification
  • Technical agreements are in place, self-inspection is active and current, and distribution arrangements are ready
  • For human medicines placed on the EU market, the safety features are affixed where appropriate

Certifying a batch with an unexpected deviation

Section 3 allows a QP to consider certifying a batch after an unexpected deviation from the marketing authorisation or GMP, provided the registered specifications for active substances, excipients, packaging materials and the product are met. The deviation must be thoroughly investigated and its root cause corrected, and continued manufacture may need a variation to the marketing authorisation.

The impact is assessed through quality risk management. That assessment evaluates the potential effect on quality, safety or efficacy and concludes that it is negligible, considers adding the batch to the ongoing stability programme, and for biological products recognises that any departure from the approved process can have unexpected effects.

Imported batches

For products made outside the EU, unless a mutual recognition agreement or similar arrangement applies, the certifying QP must also ensure the batch has undergone in a Member State a full qualitative analysis, a quantitative analysis of at least all the active substances, and all other tests needed to meet the marketing authorisation. Storage and transport conditions for the batch and any separately shipped samples must be taken into account before certification.

How Litewave fits

Several 1.7 points rest on documents: complete and endorsed records, in-process checks made, test data against the specification, investigations closed. Litewave reads paper or electronic records, checks every entry against your master record and specifications, and shows QA only the exceptions, each linked to the page it came from, so the evidence a QP relies on arrives already checked. Litewave proposes, qualified people approve, and certification stays with the QP.

Questions we get asked

Can a QP delegate the checks in Annex 16?

The points in section 1.7 may be delegated to appropriately trained personnel or third parties, relying on the pharmaceutical quality system, provided the QP has ongoing assurance that the reliance is well founded. The three points in section 1.6 the QP must personally ensure.

How long must QP certification records be kept?

Annex 16 section 1.10.1 requires the register to be kept up to date and available to the competent authority for the period set by the Member State, and in any event for at least five years.

Can a batch be shipped before it is certified?

Not to the market. Until certification, a batch stays at the manufacturing site or moves under quarantine to another site approved for that purpose, and safeguards, physical or validated electronic, must stop uncertified batches reaching saleable stock.

Sources

  1. EudraLex Volume 4, Annex 16, Certification by a Qualified Person and Batch Release
  2. Directive 2001/83/EC, Community code relating to medicinal products for human use (EUR-Lex)